Study on Doses of Inhaled ALX1 in Adults With Bronchiectasis

This study will evaluate the safety and effects of ALX1, an inhaled investigational treatment, in adults with bronchiectasis. Participants will receive either ALX1 or a placebo (a treatment with no active medicine) for 14 days. The study will compare different dose levels of ALX1 to help identify appropriate doses for future research based on safety, tolerability, and changes in predictive biomarkers.

NCT Number	NCT07731919
Lead Sponsor	Vast Therapeutics
Conditions	Bronchiectasis Adult
Enrollment	28 participants
Start Date	2026-09-01
Primary Completion	2027-03-31 (estimated)
Study Completion	2027-03-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-28